Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Levodopa jejunal infusions: patient selection & challenges

Dag Nyholm, MD, PhD, Uppsala University, Uppsala, Sweden, explores the use of jejunal levodopa infusions for the treatment of Parkinson’s disease. Jejunal infusions have been used for many years, beginning with the development of the levodopa/carbidopa intestinal gel in the 90s. Now, two marketed jejunal infusion options are available, which deliver medication directly to the small intestine for optimal absorption. Prof. Nyholm highlights that this therapy requires a team of healthcare professionals and the placement of a gastroenteric access system, but long-term experience with these treatments is extensive. The main challenge lies in accessing the small intestine, but once under control, the side effects are minimal. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Prof. Nyholm has received grant support from EU Joint Programme – Neurodegenerative Disease Research (JPND), Swedish Brain Foundation, Swedish Parkinson’s Disease Foundation, Swedish Research Council, Vinnova (Sweden’s Innovation Agency); consultancy fees from Britannia, Medtronic, NeuroDerm, NordicInfu Care, Orion, Stada; lecture fees from AbbVie and Britannia; remuneration for participating in expert panels at the websites and; and publishing royalties from Liber AB. He has participated as an investigator in clinical trials sponsored by Dizlin, GSK, Integrative Research Labs, Ipsen, Lobsor, Neurolixis, Sensidose, Solvay/Abbott/AbbVie.